Journal article
Severe Sensory Deficits but Normal CNS Development in Newborn Mice Lacking TrkB and TrkC Tyrosine Protein Kinase Receptors
The European journal of neuroscience, Vol.9(10), pp.2045-2056
Received 21 January 1997, revised 7 April 1997, accepted 18 April 1997
10/1997
DOI: 10.1111/j.1460-9568.1997.tb01372.x
PMID: 9421165
Abstract
Analysis of mice carrying targeted mutations in genes encoding neurotrophins and their signalling Trk receptors has provided critical information regarding the role that these molecules play in the mammalian nervous system. In this study we generated mice defective in both TrkB and TrkC tyrosine kinase receptors to determine the biological effects of these receptors in the absence of compensatory mechanisms. trkB(-/-);trkC(-/-) double-mutant mice were born at the expected frequency, indicating that TrkB and TrkC signalling are not required for embryonic survival. However, these double-mutant mice had a significantly shorter lifespan and displayed more severe sensory defects than their single-mutant trkB(-/-) and trkC(-/-) littermates. The most dramatic sensory deficit observed in trkB(-/-);trkC(-/-) mutant mice was the absence of vestibular and cochlear ganglia. Interestingly, these mice developed inner ear sensory epithelia in spite of the complete absence of sensory innervation. Analysis of the CNS in trkB(-/-);trkC(-/-) mutant mice revealed a well formed hippocampus, cortex and thalamus. Moreover, the pattern of expression of several neuronal markers appeared normal in these animals. These observations suggest that neurotrophin signalling through TrkB and TrkC receptors is essential for the development of sensory ganglia; however, it does not play a major role in the differentiation and survival of CNS neurons during embryonic development.
Details
- Title: Subtitle
- Severe Sensory Deficits but Normal CNS Development in Newborn Mice Lacking TrkB and TrkC Tyrosine Protein Kinase Receptors
- Creators
- Inmaculada Silos-Santiago - Department of Molecular Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USAAnne M Fagan - Department of Molecular Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USAMelinda Garber - Department of Molecular Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USABernd Fritzsch - Department of Biomedical Sciences, Creighton University, Omaha, Nebraska 68104, USAMariano Barbacid - Department of Molecular Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA
- Resource Type
- Journal article
- Publication Details
- The European journal of neuroscience, Vol.9(10), pp.2045-2056
- Edition
- Received 21 January 1997, revised 7 April 1997, accepted 18 April 1997
- DOI
- 10.1111/j.1460-9568.1997.tb01372.x
- PMID
- 9421165
- NLM abbreviation
- Eur J Neurosci
- ISSN
- 0953-816X
- eISSN
- 1460-9568
- Publisher
- Blackwell Publishing Ltd; Oxford, UK
- Number of pages
- 12
- Language
- English
- Date published
- 10/1997
- Academic Unit
- Iowa Neuroscience Institute; Biology; Craniofacial Anomalies Research Center
- Record Identifier
- 9984071687202771
Metrics
21 Record Views